|
the Fin Her trial
also used an entirely different set of chemotherapy drugs
Drs. Slamon and Piccart are reexamining the results of the North American and HERA adjuvant herceptin clinical trials focusing on those patients who had to stop herceptin early due to decreases in LVEF (heart function) in order to see if that data can be utilized to determine if those having shorter courses did just as well or not . At AACR I learned that the investigation is ongoing, hopefully with results soon.
It is generally accepted that it is considered immoral to have trials where they give patients less than the treatment they know to be beneficial--which one year of herceptin truly is-- (which is why trials normally are designed to give the standard of care treatment PLUS something they think might make it even better)
|